Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K6NS
|
|||
| Former ID |
DPR000114
|
|||
| Drug Name |
T-226293
|
|||
| Synonyms |
Triparanol; TRIPARANOL; Metasqualene; MER 29; 78-41-1; triparanolum; valip; Metasclene; Clotrox; Triparanolo [DCIT]; Hipocolestina; Acosterina; Drenaren; Diticyl; Triparanol [INN:BAN]; Triparanolum [INN-Latin]; EINECS 201-115-0; NSC 65345; BRN 2064866; 1-(4-(2-Diethylaminoethoxy)phenyl)-1-p-tolyl-2-(4-chlorophenyl)ethanol; CHEMBL187709; 2-p-Chlorophenyl-1-(p-(2-diethylaminoethoxy)phenyl)-1-p-tolylethanol; 1-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(p-tolyl)-2-(p-chlorophenyl)ethanol; NCGC00165907-02
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Preclinical | [1] | |
| Company |
Schering Plough
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H32ClNO2
|
|||
| Canonical SMILES |
CCN(CC)CCOC1=CC=C(C=C1)C(CC2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)C)O
|
|||
| InChI |
1S/C27H32ClNO2/c1-4-29(5-2)18-19-31-26-16-12-24(13-17-26)27(30,23-10-6-21(3)7-11-23)20-22-8-14-25(28)15-9-22/h6-17,30H,4-5,18-20H2,1-3H3
|
|||
| InChIKey |
SYHDSBBKRLVLFF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 78-41-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
110740, 6687838, 8154186, 16858634, 24724632, 29217665, 29225504, 49967656, 50111719, 52442310, 57323521, 103458476, 103852307, 104057017, 104312340, 117431694, 117463216, 127316187, 127316188, 127316189, 127316190, 127316191, 127316192, 127316193, 127316194, 127316195, 127316196, 127316197, 129306152, 134223593, 134339551, 134340651, 134970758, 137007264, 144205821, 162248430, 163138523, 164765975, 170466640, 179315863, 184536620, 184547379, 226501669, 249950729, 252323520
|
|||
| ChEBI ID |
CHEBI:135714
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta(24)-sterol reductase (DHCR24) | Target Info | Inhibitor | [2] |
| Melanin-concentrating hormone receptor 1 (MCHR1) | Target Info | Antagonist | [1] | |
| BioCyc | Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | |||
| Cholesterol biosynthesis III (via desmosterol) | ||||
| Cholesterol biosynthesis I | ||||
| Superpathway of cholesterol biosynthesis | ||||
| KEGG Pathway | Steroid biosynthesis | |||
| Metabolic pathways | ||||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | Tryptophan metabolism | |||
| Cholesterol biosynthesis | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
| REF 2 | Antilipemic drug-induced skin manifestations. Hautarzt. 1995 Feb;46(2):76-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.